These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 34518999)

  • 1. Management of prolactinomas in children and adolescents; which factors define the response to treatment?
    Alikasifoglu A; Celik NB; Ozon ZA; Gonc EN; Kandemir N
    Pituitary; 2022 Feb; 25(1):167-179. PubMed ID: 34518999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resistant prolactinomas: a case series of 26 patients.
    Eshkoli T; Fraenkel M; Zaid D; Cohen D; Yoel U; Tsvetov G; Gorshtein A; Goldbart A; Greenman Y; Shimon I
    Endocrine; 2022 Aug; 77(2):349-356. PubMed ID: 35604631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas.
    Di Sarno A; Landi ML; Marzullo P; Di Somma C; Pivonello R; Cerbone G; Lombardi G; Colao A
    Clin Endocrinol (Oxf); 2000 Jul; 53(1):53-60. PubMed ID: 10931080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phenotype and resistance patterns of 10 resistant prolactinomas.
    Araujo-Castro M; Abad López A; Aller Pardo J; Kanaan Kanaan L; Palacios García N
    Endocrinol Diabetes Nutr (Engl Ed); 2020 Mar; 67(3):194-204. PubMed ID: 31201099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The assessment of cabergoline efficacy and tolerability in patients with pituitary prolactinoma type.
    Bolko P; Jaskuła M; Waśko R; Wołuń M; Sowiński J
    Pol Arch Med Wewn; 2003 May; 109(5):489-95. PubMed ID: 14768178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyperprolactinemia in children and adolescents and longterm follow-up results of prolactinoma cases: a single-centre experience.
    Kontbay T; Şıklar Z; Özsu E; Uyanık R; Bilici E; Ceran A; Berberoğlu M
    Turk J Pediatr; 2022; 64(5):892-899. PubMed ID: 36305439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Start low, go slowly - mental abnormalities in young prolactinoma patients under cabergoline therapy.
    Brichta CM; Wurm M; Krebs A; Schwab KO; van der Werf-Grohmann N
    J Pediatr Endocrinol Metab; 2019 Sep; 32(9):969-977. PubMed ID: 31323004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of high-dose daily cabergoline in an adolescent patient with macroprolactinoma.
    Howell DL; Wasilewski K; Mazewski CM; Hudgins RJ; Meacham LR
    J Pediatr Hematol Oncol; 2005 Jun; 27(6):326-9. PubMed ID: 15956887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of Dopamine Agonist-Resistant Prolactinoma.
    Maiter D
    Neuroendocrinology; 2019; 109(1):42-50. PubMed ID: 30481756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide.
    Colao A; Ferone D; Lastoria S; Cerbone G; Di Sarno A; Di Somma C; Lucci R; Lombardi G
    Clin Endocrinol (Oxf); 2000 Apr; 52(4):437-45. PubMed ID: 10762286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment.
    Colao A; Di Sarno A; Sarnacchiaro F; Ferone D; Di Renzo G; Merola B; Annunziato L; Lombardi G
    J Clin Endocrinol Metab; 1997 Mar; 82(3):876-83. PubMed ID: 9062500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of Pituitary Surgery and High-Dose Cabergoline Therapy on Metabolic Profile in Patients With Prolactinoma Resistant to Conventional Cabergoline Treatment.
    Pirchio R; Auriemma RS; Solari D; Arnesi M; Pivonello C; Negri M; de Angelis C; Cavallo LM; Cappabianca P; Colao A; Pivonello R
    Front Endocrinol (Lausanne); 2021; 12():769744. PubMed ID: 34917030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnosis and drug therapy of prolactinoma.
    Ciccarelli E; Camanni F
    Drugs; 1996 Jun; 51(6):954-65. PubMed ID: 8736617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PRL-R Variants Are Not Only Associated With Prolactinomas But Also With Dopamine Agonist Resistance.
    de Castro Moreira AR; Trarbach E; Bueno CBF; Monteiro ALS; Grande IPP; Padula M; Maciel GAR; Glezer A
    J Clin Endocrinol Metab; 2023 Jun; 108(7):e450-e457. PubMed ID: 36638053
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biochemical Remission after Cabergoline Withdrawal in Hyperprolactinemic Patients with Visible Remnant Pituitary Adenoma.
    Kim K; Park YW; Kim D; Ahn SS; Moon JH; Kim EH; Lee EJ; Ku CR
    J Clin Endocrinol Metab; 2021 Jan; 106(2):e615-e624. PubMed ID: 33079168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiographic and Hormonal Regression in Prolactinomas: An Analysis of Treatment Failure.
    Akinduro OO; Lu VM; Izzo A; De Biase G; Vilanilam G; Van Gompel JJ; Bernet V; Donaldson A; Olomu O; Meyer FB; Quinones-Hinojosa A; Chaichana KL
    World Neurosurg; 2019 Sep; 129():e686-e694. PubMed ID: 31181361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of dopamine agonist resistance in prolactinoma patients.
    Vermeulen E; D'Haens J; Stadnik T; Unuane D; Barbe K; Van Velthoven V; Gläsker S
    BMC Endocr Disord; 2020 May; 20(1):68. PubMed ID: 32429916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Macroprolactinoma with secondary resistance to dopamine agonists: a case report and review of the literature.
    Tng EL; Teo AE; Aung AT
    J Med Case Rep; 2023 Mar; 17(1):96. PubMed ID: 36927797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Giant prolactinomas in men: efficacy of cabergoline treatment.
    Corsello SM; Ubertini G; Altomare M; Lovicu RM; Migneco MG; Rota CA; Colosimo C
    Clin Endocrinol (Oxf); 2003 May; 58(5):662-70. PubMed ID: 12699451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prolactinomas Resistant to Dopamine Agonists: Pathophysiology and Treatment.
    Shimon I
    Arch Med Res; 2023 Dec; 54(8):102883. PubMed ID: 37689507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.